Arcturus Therapeutics (ARCT) Misses Q4 EPS by 92c
Tweet
Share
E-mailGet Alerts ARCT Hot Sheet
Join SI Premium – FREE
Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.11), $0.92 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.77 million versus the consensus estimate of $63.22 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Diploma Plc. (DPLM:LN) to Overweight
- UBS Upgrades Celestica (CLS) to Buy
- Goldman Sachs Starts Aeva Technologies Inc. (AEVA) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
